← Back to Search

DaTscan for Dementia (PPMI Trial)

Phase 2
Waitlist Available
Research Sponsored by Ken Marek, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study intervals ranging from 3 months to 156 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Approved for 5 Other Conditions

Summary

This trial observes and collects data on various health indicators in people with Parkinson's disease and healthy individuals. The goal is to identify markers that show how the disease progresses. This information can help in developing new treatments for Parkinson's disease.

Eligible Conditions
  • Dementia
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study intervals ranging from 3 months to 156 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and study intervals ranging from 3 months to 156 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Rates of Change
Secondary study objectives
Comparison between Rates of Change
Exploratory Analysis
Predictive Value
+2 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Datscan SPECT ImagingExperimental Treatment1 Intervention
Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ioflupane I-123
FDA approved

Find a Location

Who is running the clinical trial?

Ken Marek, MDLead Sponsor
Institute for Neurodegenerative DisordersOTHER
48 Previous Clinical Trials
12,062 Total Patients Enrolled
1 Trials studying Dementia
16 Patients Enrolled for Dementia
Kenneth L Marek, MDStudy ChairInstitute for Neurodegenerative Disorders
5 Previous Clinical Trials
505,292 Total Patients Enrolled
~62 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top